Dec 16, 2019 / 12:30PM GMT
Operator
Welcome to Amarin Corporation's Conference Call to discuss the recent FDA approval of a new indication for Vascepa. This conference call is being recorded today, December 16, 2019.
I'd now like to turn the conference call over to Elisabeth Schwartz, Senior Director of Investor Relations at Amarin.
Elisabeth Schwartz - Amarin Corporation plc - Senior Director of IR
Good morning. Welcome to today's discussion about the U.S. FDA's approval of new indication and label expansion for Vascepa capsules, based on the landmark REDUCE-IT cardiovascular outcome study. The aim of this call is to focus only on matters pertaining to this recent FDA label expansion for Vascepa.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding Vascepa clinical data and cost-effectiveness analyses and expectations regarding the application
Amarin Corporation plc - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot